Microbot Medical inks deal to expand surgical robot manufacturing capabilities

The Liberty surgical robot system. [Image from Microbot Medical]Microbot Medical (Nasdaq:MBOT) announcd today that it signed a manufacturing agreement with B.Y. Medimor for its surgical robot.

Braintree, Massachusetts-based Microbot develops the Liberty single-use endovascular robotic surgical system. It designed Liberty for use in neurovascular, cardiovascular and peripheral vascular procedures. The system includes a compact design and remote operating capabilities to reduce radiation exposure and physical strain on physicians.

Microbot believes Liberty’s remote operation could potentially make it the first system to democratize endovascular interventional procedures.

The agreement with Medimor governs the manufacturing of Liberty for its first-in-human clinical trial. It also covers the initial Liberty systems expected to hit the market following the completion of regulatory requirements. Medimor provides new product introduction (NPI) solutions and…

Read more
  • 0

Microbot Medical completes pre-clinical study of endovascular surgical robot

The Liberty surgical robot system. [Image from Microbot Medical]Microbot Medical (Nasdaq:MBOT) announced today that it successfully completed an extended pre-clinical study of its surgical robot system.

Hingham, Massachusetts-based Microbot develops the Liberty single-use endovascular robotic surgical system. It designed Liberty for use in neurovascular, cardiovascular and peripheral vascular procedures. The system includes a compact design and remote operating capabilities to reduce radiation exposure and physical strain on physicians.

Key opinion leaders (KOLs) at a New York-based research lab conducted the pre-clinical study. A team of leading interventional radiologists used the system to perform dozens of catheterizations. That includes using the system’s remote operating capabilities on pre-determined vascular targets. Microbot Medical reported a 100% success rate in reaching the intended target with no observable on-site complications.

Read more

  • 0